IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients.
Chen Sabrina Tan, Shweta Anjan, Ella J Ariza-Heredia...
https://pubmed.ncbi.nlm.nih.gov/41766598/Actively Recruiting
Led by Seoul National University Hospital · Updated on 2026-10-26
80
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the immune response and safety of a respiratory syncytial virus RSV vaccine in lung transplant recipients compared to immunocompetent adults. The study aims to provide evidence to guide RSV vaccination in lung transplant recipients, who are at higher risk due to immunosuppressive therapy. This Phase 4 trial focuses on prevention and involves adults aged 19 years and older. Participants will receive a single intramuscular dose of the RSVPreF3 vaccine Arexvy. The study includes two groups lung transplant recipients aged 19 and older who are on immunosuppressive therapy, and immunocompetent adults aged 60 and older without immune-compromising conditions. Immune responses will be measured before vaccination, and at 1 month and 12 months after vaccination, with safety monitored throughout. During the study, participants will be contacted by phone 7 days after vaccination and will have a follow-up visit at 30 days to assess any adverse events. Immunogenicity assessments will include measurement of neutralizing antibodies and cell-mediated immunity. Safety evaluations will continue for up to 12 months after vaccination. The total participation period extends to about one year after vaccination.
CONDITIONS
Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
C
Chan Mi Lee, M.D., PhD.
Y
Young Hoon Hwang, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seoul National University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 month
Participants receive a single dose of the RSVPreF3 vaccine and have follow-up contacts by phone on Day 7 and a visit at Day 30 to assess safety and adverse events.
Phone call on Day 7 and 1 follow-up visit at Day 30
Duration - 12 months
Participants have blood tests to measure immune responses before vaccination, and at 1 month and 12 months after vaccination, with safety monitored throughout the study.
Blood samples at pre-vaccination, 1 month, and 12 months post-vaccination
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Chen Sabrina Tan, Shweta Anjan, Ella J Ariza-Heredia...
https://pubmed.ncbi.nlm.nih.gov/41766598/Michael Melgar, Amadea Britton, Lauren E Roper...
https://pubmed.ncbi.nlm.nih.gov/37471262/Erick F Mayer, Ann R Falsey, Cameron R Wolfe...
https://pubmed.ncbi.nlm.nih.gov/41711453/Fiona P Havers, Michael Whitaker, Michael Melgar...
https://pubmed.ncbi.nlm.nih.gov/37796742/M Tin Tin Htar, M S Yerramalla, J C Moïsi...
https://pubmed.ncbi.nlm.nih.gov/32052719/Sun Hee Na, Hyeon Jae Jo, Jin Ju Park...
https://pubmed.ncbi.nlm.nih.gov/39283316/Edward E Walsh, Gonzalo Pérez Marc, Agnieszka M Zareba...
https://pubmed.ncbi.nlm.nih.gov/37018468/Hung Fu Tseng, Lina S Sy, Bradley Ackerson...
https://pubmed.ncbi.nlm.nih.gov/32591787/Alberto Papi, Michael G Ison, Joanne M Langley...
https://pubmed.ncbi.nlm.nih.gov/36791160/Amadea Britton, Lauren E Roper, Camille N Kotton...
https://pubmed.ncbi.nlm.nih.gov/39146277/Seoul National University Hospital
Lead Sponsor